Company Profile

Discovery Genomics Inc (AKA: DGI)
Profile last edited on: 12/1/20      CAGE: 46LD9      UEI:

Business Identifier: Gene delivery and discovery; Gene therapies for blood diseases
Year Founded
2000
First Award
2003
Latest Award
2013
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

614 Mckinley Place Ne
Minneapolis, MN 55413
   (612) 624-6736
   scottm@discoverygenomics.net
   www.discoverygenomics.net
Location: Single
Congr. District: 05
County: Hennepin

Public Profile

In March 2016, Gene therapy company Immusoft - also an SBIR involved firm - acquired Discovery Genomics along with its Sleeping Beauty Transposon System designed to deliver genes into cells without using a virus. It was reported that the acquisition will give Immusoft the ability to use Sleeping Beauty with B cells and its own Immune System Programming (ISP) platform to treat diseases. Gene therapy is a technique for adding a corrective gene to prevent or alleviate a disease state. Discovery Genomics, Inc. (DGI) defines itself as a gene therapy company organized around curing disease by delivering therapeutic genes that allow the body to heal itself. Discovery Genomics, Inc. had been a functional genomics company created to discover gene functions, conduct drug target validations, and design therapeutic agents based on genomics information. With a primary focus o gene therapies for blood diseases, he company holds exclusive licenses from the University of Minnesota to develop technologies using a proprietary Morphant(TM) technology and to the use of the Sleeping Beauty Transposon(TM). Both technologies may be used for functional genomics and the discovery of drug targets. The transposon may have applications in gene therapy. Morphant(TM) "knock-downs" are used to suppress and thereby study the functions of particular genes. The Zebrafish model system is a faster and less expensive approach to gene discovery than other vertebrate model systems

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 2 NIH $3,156,566
Project Title: Sleeping Beauty-Mediated Gene Therapy for Hemophilia A
2013 1 NIH $200,244
Project Title: Sleeping Beauty Mediated Therapy For Alpha V Beta 6-Expressing Pancreatic Cancer
2010 1 NIH $270,673
Project Title: Sleeping Beauty-Mediated Gene Therapy Of X-Linked Scid
2008 2 NIH $1,639,489
Project Title: Transposon-mediated Gene Therapy for Fanconi Anemia
2008 1 NIH $290,918
Project Title: Delivery Of Sleeping Beauty Transposons To Dog Liver For Gene Therapy

Key People / Management

  John Haaland -- President and CEO

  R Scott McIvor -- President

  Stephen C Ekker -- Founder

  Jeffrey J Essner

  Perry B Hackett -- Authorized Organizational Representative

  Kendra A Hyland

  David A Largaespada -- Founder

  John Ohlfest

Company News

There are no news available.